MedTrace Logo

Aflibercept Injection for Proliferative Diabetic Retinopathy

NCT01805297 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-12-27

Study results available
· View outcomes & findings →

Summary

To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.

Conditions

  • Vitreous Hemorrhage

Interventions

DRUG

Intravitreal Aflibercept Injection

One time 2.0mg aflibercept injection, following pars plana vitrectomy.

OTHER

Standard Vitrectomy

Surgical intervention

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Robert E Leonard, MD · Dean McGee Eye Institute

  • Vinay A Shah, MD · Dean McGee Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-02-28
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805297 on ClinicalTrials.gov